Ionis Pharmaceuticals (IONS) Return on Sales (2016 - 2025)
Ionis Pharmaceuticals has reported Return on Sales over the past 17 years, most recently at 0.75% for Q4 2025.
- Quarterly results put Return on Sales at 0.75% for Q4 2025, up 121.0% from a year ago — trailing twelve months through Dec 2025 was 0.0% (up 64.0% YoY), and the annual figure for FY2025 was 0.0%, up 64.0%.
- Return on Sales for Q4 2025 was 0.75% at Ionis Pharmaceuticals, up from 0.82% in the prior quarter.
- Over the last five years, Return on Sales for IONS hit a ceiling of 61.78% in Q2 2025 and a floor of 1.2% in Q1 2024.
- Median Return on Sales over the past 5 years was 0.54% (2021), compared with a mean of 2.75%.
- Biggest five-year swings in Return on Sales: plummeted -409bps in 2022 and later skyrocketed 6207bps in 2025.
- Ionis Pharmaceuticals' Return on Sales stood at 3.74% in 2021, then tumbled by -109bps to 0.35% in 2022, then skyrocketed by 92bps to 0.03% in 2023, then tumbled by -1524bps to 0.46% in 2024, then surged by 261bps to 0.75% in 2025.
- The last three reported values for Return on Sales were 0.75% (Q4 2025), 0.82% (Q3 2025), and 61.78% (Q2 2025) per Business Quant data.